Oxford BioTherapeutics (OBT) has appointed Dr Michael Moore non-executive chairman. He joins the company following five years spent at UK …
Roche is set to pay $160 million (£315 million) to buy UK biotech company Piramed, a move which will further …
Piramed and Domainex are among the cutting-edge companies which have been recognised as the best of the UKs biotech sector.UK …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

